



Contacts:

Investors

EVC Group

Dahlia Bailey/Douglas Sherk

415-896-6820

Media

EVC Group

Steve DiMattia/Chris Gale

646-201-5445

FOR IMMEDIATE RELEASE

**PHARSIGHT TO PRESENT ON MODELING AND SIMULATION AT
SPANISH PHARMACOLOGICAL SOCIETY ANNUAL MEETING**

*Dr. John Lukas Will Present on the Strategic Value of Drug-Disease Modeling and
Advanced Visualization Tools to Improve Drug Development Decision-Making*

MOUNTAIN VIEW, Calif., September 15, 2008 – Pharsight Corporation (NASDAQ: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that John C. Lukas, Ph.D., senior scientist, Strategic Consulting Services, has been invited to speak to members of the European biotechnology and pharmaceutical industries attending the 30th Annual Congress of the Spanish Pharmacological Society (SEF). The SEF Annual Congress will be held at the Palacio de Congresos y de la Música in Bilbao, Spain from September 17-19, 2008. Dr. Lukas will present at SEF on September 18.

Dr. Lukas' presentation, entitled, "Impact of Modeling and Simulation in Drug Development," will include an oncology case study on the use of drug-disease modeling and clinical trial simulations to predict efficacy and survival benefit of anticancer agents. Dr. Lukas will also describe how Pharsight's novel visualization software, Drug Model Explorer® (DMX®), can help clinical development teams explore the modeled efficacy and safety profiles of new drug candidates versus competing therapies.

"Model-based drug development continues to show value for enhancing understanding of complex diseases in quantitative terms, and for improving the confidence of drug development decisions," said John E. Murphy, DrPH, senior vice president of Pharsight Consulting Services. "The application of drug-disease models to quantify expected clinical response of new anticancer therapies, including change in tumor size as a robust predictor of survival, can support critical oncology program strategies and study design decisions. This becomes particularly valuable in light of the high failure rate for late-stage cancer trials. Used in conjunction with drug-disease modeling, novel visualization technology such as DMX can help global drug development teams interact with model-based results. Pharsight is pleased to be invited to SEF, and to share our experience with industry colleagues and fellow practitioners of modeling and simulation."

Additional information about the SEF Congress can be found at www.socesfar.com.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at www.pharsight.com.

Forward Looking Statements

The statements in this press release related to the functionality, performance, and benefits of the DMX software are forward looking statements. Forward-looking statements are inherently speculative, and the actual results and customer's experience may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations and customers may not perceive the benefits of the DMX to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on August 13, 2008. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight, Drug Model Explorer and DMX are registered trademarks of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.